A possible role for immunogenetic factors in myositis developing after vaccination in the pre-covid-19 era
Immunogenetic factors may influence the likelihood of developing MAV. Further studies of larger, deeply phenotyped populations are needed to confirm these associations and could inform personalized risk assessments and targeted interventions, thereby enhancing vaccine safety.
Authors
- Janardan P. Pandey (ORCID: https://orcid.org/0000-0001-9992-4737)
- Lisa G. Rider (ORCID: https://orcid.org/0000-0002-6912-2458)
- Ejaz A. Shamim (ORCID: https://orcid.org/0000-0003-0992-056X)
- Frederick W. Miller (ORCID: https://orcid.org/0000-0003-2831-9593)
- Eaman Alhassan (ORCID: https://orcid.org/0000-0002-1459-7376)
- Anna P. Patnaik
Institutions
- Johns Hopkins University (US)
- Medical University of South Carolina (US)
- Johns Hopkins Medicine (US)
- National Institute of Environmental Health Sciences (US)
- National Institute of Nursing Research (US)
- National Institute of Neurological Disorders and Stroke (US)
- Colorado Permanente Medical Group (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3389/fimmu.2025.1539659
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health